Recombinant Mouse Anti-DENV E proteins Antibody (Ab513) (CAT#: PABL-068)

Figure 1 In Vitro Neutralization Comparing Ab513 and Its Predecessor Forms, 4E5A and 4E11.

Comparison of neutralizing profiles of Ab513 (♦), 4E5A (▲) and 4E11 (▼). DENV-1 (Hawaii.44), DENV-2 (NGC), DENV-3 (H87) and DENV-4 (BC287/97) were tested. Ab513 neutralized all of the viruses tested and exhibited equivalent or superior activity to 4E11 and 4E5A.

Robinson, L.N., Tharakaraman, K., Rowley, K.J., et al. (2015). Structure-Guided Design of an Anti-dengue Antibody Directed to a Non-immunodominant Epitope. Science, 162(3), 493-504.

Figure 2 Enhanced virus infection in THP-1.2S cells with addition of either chimeric 4G2 or Ab513.

Robinson, L.N., Tharakaraman, K., Rowley, K.J., et al. (2015). Structure-Guided Design of an Anti-dengue Antibody Directed to a Non-immunodominant Epitope. Science, 162(3), 493-504.

Figure 3 In Vivo Activity of Ab513 in Humanized Mice.

(C–F) Comparison of human platelet levels in uninfected and infected humanized mice (humice) without treatment or treated with an isotype control Ab ("Control Ab") or Ab513. The dashed line indicates the average of human platelet counts in uninfected humice. Results are shown as the average counts of human platelets per microliter of blood at different days post-infection (n = 5–7).

Robinson, L.N., Tharakaraman, K., Rowley, K.J., et al. (2015). Structure-Guided Design of an Anti-dengue Antibody Directed to a Non-immunodominant Epitope. Science, 162(3), 493-504.

Figure 4 Ab513 Protects Animals from Enhanced Disease.

(A) Five- to six-week-old AG129 mice born to DENV-1 immune mothers were infected with DENV-2; included was an uninfected control (black). On day 1 post-infection, infected mice were either treated with 25 mg/kg of Ab513 (green) or isotype control antibody (red). On day 6 post-infection, the extent of vascular leakage in the mice were assessed by Evans blue assay. (B and C) A group of A129 infected pups was followed daily. (B) Survival curves of four cohorts (n = 8): untreated, receiving a control antibody (Ctrl mAb), or 5 mg/kg or 25 mg/kg Ab513. Statistical inferences were made by pairwise comparisons for each treatment group to the control group, considering the survival of both. Ab513 at all doses had a significant effect on survival(C). Assessment of mean clinical score of the three treatment cohorts.

Robinson, L.N., Tharakaraman, K., Rowley, K.J., et al. (2015). Structure-Guided Design of an Anti-dengue Antibody Directed to a Non-immunodominant Epitope. Science, 162(3), 493-504.